Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine in Generalized Anxiety Disorder
NCT00135525Phase 2Completed
- Sponsor
- GSK
- Start
- May 2003
- Primary completion
- Oct 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Paroxetine with Placebo (2 arms). Primary endpoint: Hamilton Anxiety Scale Total Score at 8 weeks. Started May 2003; status: completed.
02
Drugs
paroxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00135525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135525.